Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Acquires Protein Research Technology from GenWay Biotech

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has expanded its proteomics research products offerings through the acquisition of the Seppro affinity depletion technology and a library of 700 avian-derived antibodies from GenWay Biotech.
The Seppro products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples, said Sigma. The technology allows researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins.
The acquisition includes current inventory, production technology, and all future rights to produce and distribute the product lines, said Sigma. It adds to the firm’s current depletion product offerings, such as its ProteoPrep kits for the removal of highly abundant proteins from human serum and plasma.
The St. Louis-based firm said that the library of 700 polyclonal IgY antibodies acquired from San Diego-based GenWay marks its first IgY antibody offering.
Further terms of the acquisition were not provided.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.